Cancer Research and Therapy Connect

Long COVID and Cancer Biology: Distinguishing Mechanistic Overlap from Evidence Across Cancer-Related Outcomes

Vol. 2

The Circadian–Spliceosome Axis: A Temporal Dimension of Transcriptomic Heterogeneity in Prostate Cancer

Vol. 2

Pediatric Pure Erythroid Leukemia: Diagnostic Challenges, Immunophenotypic Features, Molecular Pathogenesis, and Practical Diagnostic Approach

Vol. 2

0 citations

Immunotherapy in Glioblastoma: Why Has Progress Been So Difficult?

Vol. 2

0 citations

July 22, 2026

Chitosan Nanoparticle Delivery of Prunus africana (Hook.f) Kalkman Attenuates TGF-β/SMAD3-Driven Epithelial–Mesenchymal Transition to Suppress Prostate Cancer Metastasis

Vol. 2

0 citations

June 26, 2026

Tumor Suppressor Gene Loss and Immune-Epigenetic Reprogramming

Vol. 2

0 citations

May 22, 2026

Chrono-Adaptive Resistance Disruption (CARD): A Novel Pharmacological Framework to Address Anticancer Drug Resistance

Vol. 2

Drug resistance in anticancer therapy has long been a major challenge in oncology, biomedical, and pharmacological research. Despite numerous efforts targeting molecular and pathway-level mechanisms and evaluating combin...

0 citations

March 31, 2026

Here, There, and Everywhere: Alpha-Fetoprotein in Cancer Immunotherapy

Vol. 2

Alpha-fetoprotein (AFP) delivers nutrients to immature cells in a shuttle-like manner via alpha-fetoprotein receptor (AFPR)-mediated endocytosis. A small subset of immature myeloid-derived suppressor cells (MDSCs) acts a...

0 citations

March 26, 2026

Association of 12q21.32 cn-LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

Vol. 2

0 citations